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meliltus. The pathogenesis of the multiple structural lesions in diabetic
nephropathy remains debated, and likely is multifactorial. The uniform
thickening of the renal basement membranes lining the glomerular and
tubular elements appears to be a consequence of the metabolic pertur-
bations which are directly related to hyperglycemia. While most inves-
tigations have focused on the increased accumulation of extracellular
matrix in the glomerular basement membrane and the mesangium, and
their relation to derangements in glomerular function, little is known
regarding the pathogenesis and the significance of the tubulointerstitial
changes and the thickened tubular basement membrane (TBM). It is
possible that these latter changes are causally related to the cellular
hypertrophy of the renal tubular epithelium that lines the TBM. It has
been postulated that in the earlier stages of the disease, hyperglycemia
induces renal tubular hypertrophy and stimulates the synthesis of the
various matrix components which are normal constituents of the TBM.
Later, the structural composition of the TBM is susceptible to further
modifications by non-enzymatic glycation, and this aberrant process
may impart a relative resistance to matrix degradation leading to a slow
turnover. In vitro investigations on murine proximal tubule cells in
culture have provided evidence that elevated ambient glucose is a
sufficient stimulus for cellular hypertrophy and increased biosynthesis
of collagen type IV, the predominant constituent of TBM. High glucose
levels increase steady-state collagen IV mRNA, partly due to tránscrip-
tional activation of cis-acting elements of the gene which are controlled
by putative glucose-responsive trans-acting proteins. This effect of
hyperglycemia may be the consequence of increased activity of the
polyol pathway, with attendant alterations in cellular myo-inositol
metabolism. Treatment with sorbinil, an aldose reductase inhibitor, or
supplementation of the medium with supra-physiologic levels of myo-
inositol, prevents the stimulation by high glucose of the increased
secretion and biosynthesis of collagen IV. The glucose-induced cellular
hypertrophy, however, is minimally affected by these maneuvers, and
may result from activation of humoral or local mediators including
transforming growth factor-p.
In considering the structural lesions which characterize the
nephropathy of diabetes mellitus, much attention has been
focused on the glomerulus. However, and as was recently
reviewed [1], the contribution of non-glomerular lesions to the
clinical spectrum of diabetic nephropathy has been much less
appreciated, although careful studies have established that
tubulojnterstjtjal fibrosis [2, 3] and renal arteriosclerosis [4, 5]
are important factors in the development of ischemic or oblit-
erative glomerulosclerosis. A full understanding of the mecha-
nisms that culminate in irreversible kidney failure requires a
closer look at the status of the tubulointerstitium in diabetes
mellitus.
© 1993 by the International Society of Nephrology
Nephromegaly is also an early feature of the involvement of
the kidney in diabetes mellitus and is predominantly reflective
of increased renal tubule mass, mostly due to cellular hypertro-
phy of the tubulo-epithelium [6—8]. The importance of this
lesion in the development of abnormalities in kidney function
remains unsettled; it is speculated that the hypertrophied cell
provides a priming factor for the initiation or maintenance of a
fibrosing process in the tubulointerstitial compartment [1]. This
is somewhat analogous to the relationship between diabetic
glomerular hypertrophy and the development of glomeruloscle-
rosis [9].
Within the broader context of examining the pathobiology of
the renal tubulointerstitium in diabetes, this review will specif-
ically focus on the status of the tubular basement membrane
(TBM). Available data on the morphology and composition of
this structure will be presented. The metabolism of collagen
type IV, the most abundant constituent of the TBM, will be
reviewed. Evidence is provided relating the central influence of
elevated ambient glucose on renal growth and extracellular
matrix production, with a consideration of the potential patho-
genetic mechanisms.
Early TBM changes in diabetes and the relation to tubular cell
hypertrophy
The abnormalities of the TBM in diabetes may be conve-
niently divided into two varieties: In the early phase of the
disease there appears to be an acute increase in TBM mass
which accompanies the development of renal hypertrophy; this
is followed by the conspicuous thickening of the TBM which
does not become apparent until a few years have elapsed.
The early changes in TBM mass are best appreciated by
considering the induction phase of experimental diabetes.
Seyer-Hansen, Hansen and Gunderson [7] examined rat kidney
growth in streptozotocin-induced diabetes by morphometric
analysis of various anatomical structures at different intervals
after the onset of the disease. After only four days, proximal
tubule cell volume and epithelial cell height were significantly
increased (by at least 20%). This was later accompanied by
significant increases in tubule length and luminal diameter. It is
reasonable to assume that TBM dimensions, particularly the
surface area, must have also increased as an accompaniment to
acute renal tubular hypertrophy. Moreover, it can be argued
that, triggered by some of the anabolic events that are restricted
to the kidney, a substantial acceleration in TBM synthesis must
take place so as to enlarge TBM area (or volume). This
argument is analogous to that previously made by Osterby and
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Gundersen [10] in their study on the fast accumulation of
glomerular basement membrane (GBM) material in experimen-
tal diabetes that an acute increase in the synthetic rate of GBM
constituents is necessary in order to explain the increase in
GBM mass which accompanies acute glomerular hypertrophy.
At this early stage, alterations in the rate of degradation of
membrane components play a minor role, if any; even a total
inhibition of degradation, which itself is a very slow process
[11], would not lead to the observed changes. In considering the
subsequent phases of diabetic nephropathy, this review will
later present evidence that, in addition to increased synthesis,
decreased breakdown of basement membrane (BM) compo-
nents, particularly the collagens, may participate in the accu-
mulation of extracellular matrix.
Among the metabolic derangements that accompany the
diabetic state, hyperglycemia represents a necessary, if not
sufficient, factor for the development of some of the renal
manifestations of diabetes mellitus. To examine the isolated
influence of elevated ambient glucose on renal cell metabolism,
and to avoid the complicating roles of an altered metabolic
milieu or the effects of renal hemodynamics on the process of
diabetic renal hypertrophy, we have previously developed a cell
culture system in mouse proximal tubule epithelial cells where
we could test the effects of elevated glucose concentration on
cell growth and extracellular matrix biosynthesis [12]. Exposing
the cells for 72 hours to serum-free medium containing 25 mM
D-glucose resulted in significant cellular hypertrophy, as de-
fined by an increase in cell size by cytofluorometry, and by
increased total protein content and synthesis when compared to
cells grown in 5.5 mrsi D-glucose [12]. This response was
independent of changes in medium osmolality. Parallel studies
also demonstrated that the high glucose medium stimulated the
secretion of collagen type IV by approximately twofold. There
was also a concordant increase in steady state levels of al(IV)
mRNA, providing evidence for increased collagen synthesis.
Rates of collagen degradation were not measured in these
short-term studies [12].
In streptozotocin-induced diabetic renal hypertrophy, in situ
hybridization studies have demonstrated an early increase in
collagen type IV mRNA in the hypertrophied proximal tubule
cells [13]. Moreover, increased synthesis of collagen type IV is
also a feature of other models of renal hypertrophy such as in
compensatory hypertrophy following partial kidney ablation
[14] and in angiotensin Il-induced proximal tubule cell hyper-
trophy [15]. In the latter in vitro model, we have demonstrated
that the hypertrophogenic effect of angiotensin II was additive
to that produced by elevated ambient glucose [16].
In summary, the development phase of renal tubular hyper-
trophy in diabetes mellitus is accompanied by an early increase
in the mass of the normal constituents of the TBM. In vitro
studies provide evidence that high glucose levels, independent
of any hormonal factors, appear to be a major stimulus for the
increased synthesis of collagen type IV by proximal tubule cells
and for the induction of hypertrophy of these cells.
TBM morphology in diabetes
The renal TBM and GBM, like some basement membranes in
other tissues, undergo a progressive thickening which develops
slowly over several years [17]. The increase in width of the
TBM is almost uniform although splitting and layered thicken-
ing have also been described [18]. Views regarding TBM
morphology in diabetes have long been based on subjective
interpretation of biopsy or autopsy material, and in sharp
contrast to the extensive studies on the GBM, there are
virtually no detailed morphometnc or ultrastructural studies
devoted to the TBM in diabetes. Still lacking are large popula-
tion surveys to derive data on mean and range of TBM width in
normal adults similar to those involving the GBM [19]. Limited
quantitative data were obtained in a study of renal biopsies from
seven pairs of identical twins who were discordant for insulin-
dependent (type 1) diabetes [20]. In each pair, the diabetic twin
had a thicker TBM than the respective non-diabetic sibling. On
average, the TBM of patients was 1100 nm, representing an
almost 50% increase in thickness [20]. When it was possible to
differentiate between proximal and distal tubules, there were no
consistent regional differences between the widths of their
basement membranes. Similarly, GBM width in the diabetic
twins (average width approximately 500 nm) exceeded that in
the nondiabetic twins in each instance (approximately 330 nm).
In this study [20], values for muscle capillary basement mem-
brane width in the diabetic twins did not differ from those in
their siblings. These results were interpreted to indicate that the
thickening of the TBM (and GBM) is a consequence of the
metabolic perturbations of the diabetic state, rather than a
generalized, hereditary disturbance in all basement membranes.
Because only two of the diabetic cases had advanced glomeru-
lar lesions (characterized by hypertension, albuminuria and
reduced creatinine clearance), it appears that TBM thickening
occurs relatively early, that is, during the clinically-silent
course of the disease.
Several studies utilizing immunohistochemical techniques
have revealed conspicuous linear binding of albumin and IgG
along the length of the thickened TBM in kidneys from diabetic
subjects [21, 22]. It is generally accepted that this phenomenon
represents passive entrapment of circulating proteins rather
than an active immune process. It also remains speculative
whether this abnormality plays any role in the development of
TBM thickening.
TBM composition in diabetes
Limited available data suggest that, in addition to the gener-
alized increase in TBM mass in diabetes (particularly the
collagenous component), distinctive qualitative changes in the
biochemical composition of the TBM also occur. Analysis of
amino acid and carbohydrate content in post-mortem speci-
mens from five diabetic subjects showed a significant increase
in hydroxylysine (and a reciprocal decrease in lysine) in their
TBM as compared with specimens from eight non-diabetic
subjects [23]. This finding was similar to that reported for
diabetic GBM in some, but not all studies [reviewed in 24—27].
There was also a relative increase in methionine and a relative
decrease in haif-cystine, valine, leucine and histidine [23].
Hydroxyproline content was only marginally increased, while
the content of glycine, by far the most abundant amino acid
residue, was not different [23].
The carbohydrate composition of the TBM in diabetic sub-
jects was generally increased, due to significant increases in
galactose and N-acetylglucosamine content, and only a slight
increase in glucose content [23]. It should be noted that while
this study [23] did not detect significant changes in sialic acid
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residues in either TBM or GBM, multiple other studies have
documented a significant reduction in renal sialic acid content
[reviewed in 24—27]; this is possibly due to the increased
activity of the degradative enzyme, sialidase, in the renal cortex
[28]. Furthermore, significant reductions in sialic acid residues
in renal matrices may not become evident until the diabetes is
far advanced.
The macromolecular composition of the TBM in diabetes has
been examined by immunohistopathologic studies. Using this
technique, Falk et al [29] reported that the TBM of diabetic
subjects undergoes polyantigenic expansion of various intrinsic
basement membrane constituents including collagen types IV
and V, laminin and fibronectin. These findings were encoun-
tered in early, moderate and advanced stages of diabetic
nephropathy.
In investigations which focused on the monomeric elements
which make up the ultrastructural assembly of collagen type IV
molecules, Desjardins et al [30] utilized the protein A-gold
immunocytochemical technique in kidney specimens from
streptozotocin-diabetic rats and found that the labeling intensi-
ties of al(IV), a2(IV), and a3(IV), but not a4(IV), were
markedly increased along the TBM of diabetic kidneys. The
fate of the recently discovered a5(IV) collagen chain in the
diabetic TBM remains a subject of future investigation. How-
ever, it should be noted that in the normal kidney the localiza-
tion of a5(IV) chain is virtually restricted to the glomerulus [311.
Nevertheless, it is evident from previous studies that the
diabetic state may lead to disproportionate increases in the
individual collagenous elements which comprise the renal base-
ment membranes [29, 30], and may thus alter the functional
properties of these structures.
Superimposed on the modifications in the intrinsic composi-
tion of the collagenous elements of renal matrices, the process
of non-enzymatic glycation [32] can also impart further struc-
tural alterations which may play a role in further modifications
in the metabolism and behavior of the matrix (see also below).
It has been demonstrated that collagen type IV derived from the
kidneys of diabetic subjects contains increased amounts of
ketoamine-linked hexose, resulting from the non-enzymatic
condensation of glucose with lysyl- and hydroxylysyl residues
[33]. The TBM involvement by this process has been demon-
strated in immunohistochemical studies in the kidney of dia-
betic rats [34]. In these studies, antiserum against glucitol-
lysine localized the glycated protein to the TBM and the brush
border of the proximal convoluted tubule; in control rats, only
the brush border was weakly reactive. It can also be assumed
that the long-lived TBM macromolecular constituents are fur-
ther modified by the irreversible binding to advanced glycosy-
lation end-products (AGE) [35, 36].
Increased collagen synthesis in diabetes
Several lines of evidence suggest that the increased content
of extracellular matrix in the diabetic kidney is partly due to
increased rates of synthesis, particularly in the early phases of
the disease [27]. To some degree, this may relate to the
kidney-specific anabolic effects of diabetes which stimulate the
synthesis of RNA, proteins and structural glycoproteins [37,
38], and which represent crucial effector mechanisms for the
development of renal hypertrophy [reviewed in 6, 39]. As
discussed above, the fast accumulation of basement membrane
material is commensurate with the induction phase of diabetic
renal growth [10].
The study of the metabolism of renal basement membranes in
diabetes has been virtually confined to isolated glomeruli or
GBM [26, 27]. Conclusions regarding the status of TBM metab-
olism can only be indirectly implied from studies on whole
kidney specimens. This may be a good approximation given the
fact that the renal tubule comprises the bulk of the renal cortex.
Steady state levels of mRNA encoding extracellular matrix
molecules have recently been measured in kidneys of animals
with experimental diabetes in order to examine the mechanisms
of increased matrix synthesis. Poulsom et al [40] found a
twofold increase in laminin B I mRNA in rat kidneys after 28
weeks following streptozotocin-induced diabetes. In contrast,
levels for al(IV) mRNA were not increased, and in fact showed
a progressive decline with age in both the diabetic and the
non-diabetic animals [40]. The study of Ledbetter et al in the
obese KKAy mouse, a model of spontaneous non-insulin-
dependent diabetes, reached opposite conclusions [41]. Renal
cortical levels of al(IV) mRNA were increased in the diabetic
mice at four and six months of age (2- and 4-fold, respectively),
while mRNA levels encoding laminin B 1 and proteoglycan core
protein were not different from those of age-matched non-
diabetic mice. The level for a2(IV) mRNA was also increased in
the kidneys of diabetic animals. The increase in collagen type
IV mRNA in diabetic kidneys has been also reported in
streptozotocin-diabetic mice [42]. Furthermore, in situ hybrid-
ization studies in streptozotocin-diabetic rats have localized the
increase in al(IV) mRNA to the straight segment of proximal
tubule cells [131, implying increased TBM collagen synthesis.
Renal cortical levels of fibronectin mRNA have also been
shown to be variably increased in streptozotocin-induced dia-
betic rats (a 3-fold average increase) [43]. Taken together, these
studies provide evidence that the diabetic state stimulates the
synthesis of several extracellular matrix molecules in the kid-
neys of experimental diabetes, and that this effect is partly
related to increased mRNA levels encoding these molecules.
Hyperglycemia per se could represent a dominant factor in
mediating this effect since high ambient glucose concentration
in culture medium has been shown to increase the mRNA levels
of several matrix moieties in glomerular mesangial cells [441 and
al(IV) mRNA levels in proximal tubule cells [12], as demon-
strated in Figure 1.
Using nuclear run-off assays we demonstrated in the latter
study [12] that collagen type IV gene transcription rate is
stimulated when the proximal tubule cells are cultured in 25 mr.t
D-glucose compared with 5.5 mM D-glucose. Transcriptional
control of collagen type IV gene by high glucose media was also
evident in experiments using transient expression studies (un-
published data). This involved the transfection of proximal
tubule cells [12] with plasmid p184 [15] containing the CAT
reporter gene linked to a genomic fraction of the mouse collagen
type IV gene which includes the promoter and enhancer ele-
ments (gift of Dr. P. Killen). The results show (Fig. 2) that high
medium glucose stimulates the CAT activity several-fold, thus
providing evidence that high glucose modulates the interaction
of putative transcription factors with specific cis-acting DNA
sequences which regulate transcription.
There is also a general tendency towards increased specific
activity of synthesis-related post-translational enzymes in the
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Fig. 1. Autoradiogram of a northern blot in mouse cortical tubule
(MCT) cells derived from proximal tubule. Cells cultured for 48 hours in
serum-free medium containing 450 mgldl, or 25 m glucose (HG)
expressed more than twofold higher levels of the mRNA for the alpha-i
chain of type IV collagen than in 100 mg/dl, or 5.5 m glucose (NG).
The same filter was stripped and reprobed with GAPDH to control for
equal RNA loading and transfer.
renal cortex of diabetic animals which can lead to increased
collagen synthesis in the TBM and GBM [reviewed in 26, 27].
Many investigations have demonstrated, at least during some
stages of the disease, increased activity of glucosyltransferase,
galactosyltransferase, prolyl-4-hydroxylase and lysyl-hydroxy-
lase [45, 46]. Additional evidence, although indirect, for en-
hanced collagen type IV synthesis in diabetes, has been derived
from the demonstration of increased circulating levels of the
disulfide-rich 7S domain of collagen IV, which also correlated
with increased GBM synthesis [47] and the advanced degree of
renal involvement by the diabetic state [48].
Decreased collagen degradation in diabetes
Little is known about the turnover rate of the TBM, however,
it can be assumed to be quite slow if one considers what is
known about the very slow turnover rate of other matrices such
as the GBM, which can be quantitated over a period of several
weeks [11, 49]. The degradative rate of the GBM is diminished
further in streptozotocin-diabetic rats [50, 51].
The activities of several renal cortical enzymes involved in
collagen degradation are diminished in experimental diabetes
including cs-glucohydrolase, f3-D-galactosidase, and poorly
characterized collagenase and lysosomal enzyme [52, reviewed
in 26, 27].
It should be pointed out that increased collagen synthesis and
decreased degradation are not mutually exclusive events and
may be operating simultaneously but at different rates; in-
creased synthesis may predominate early, while decreased
degradation occurs later in the course of the disease [27].
Cellular mechanisms
In considering the effects of diabetes on the morphology and
the metabolism of the TBM, we are faced with a scarcity of data
regarding the cellular mechanisms which underlie these effects.
In general, however, a few theories can be advanced to explain
1 2 3 4
Fig. 2. Transcriptional control of collagen type IV gene by elevated
ambient glucose in cultured MCT cells, a mouse proximal tubule cell
line. The cells were transfected with various plasmids containing the
chioramphenicol acetyltransferase (CAT) reporter gene, and CAT
enzyme activity was then determined as previously described [12]. The
autoradiographs show TLC-separated acetylated (upper bands), that is,
CAT activity, from unacetylated '4C-chloramphenicol. Lane 1 pAo-
CAT, a negative-control promoterless plasmid; lane 2: pSV2-CAT, a
positive-control plasmid containing the SV4O promoter and enhancer;
lane 3: p184, a plasmid containing a genomic fraction of the mouse
collagen type IV gene which includes the promoter and enhancer
elements (the MCT cells were cultured for 48 hours in 5.5 m D-glucose);
and lane 4: MCT cells transfected with p184 but cultured for 48 hours in
25 mri D-glucose. The measured CAT activity in high-glucose culture
was more than threefold higher than for normal-glucose culture (scin-
tillation counting of cut-out bands). Not shown is the absence of any
effect of ambient glucose on the CAT activity of the negative or positive
control plasmids [121.
some of the pathophysiologic consequences of hyperglycemia,
the predominant feature of the diabetic state.
Nonenzymatic glycation reactions resulting in both the early
ketoamine linkages and the later-developing advanced glycosy-
lation end-products (AGEs) often affect long-lived matrix con-
stituents, particularly collagens, and may contribute in a signif-
icant way to aberrations in the structure and function of
basement membranes [32, 35, 36, 53, 54]. Decreased degrada-
tion of matrix molecules may, in part, be a consequence of
these reactions [55]. Future studies are required to elucidate the
exact role of these abnormalities in the pathogenesis of diabetic
nephropathy.
Increased flux through insulin-independent pathways for in-
tracellular glucose utilization, particularly the polyol pathway,
has been advanced as a contributory factor in mediating the
early functional changes in certain diabetic target organs [56—
58]. The resultant cellular dysfunction may relate to abnormal-
ities in hormone responsiveness and signal-transduction path-
ways, which in part are induced by disordered cellular myo-
inositol metabolism; myo-inositol supplementation may correct
some of the disturbances that are attributed to increased
activity of the polyol pathway [57, 58].
Evidence in favor of an involvement of the polyol pathway in
some of the renal manifestations of diabetes has been provided
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by our recent demonstration that the early glomerular hyperfil-
tration in streptozotocin-induced diabetic rats can be amelio-
rated by a diet supplemented with myo-inositol (1%), or by the
administration of sorbinil, an aldose reductase inhibitor (ARI)
which blocks the rate-limiting step in the polyol pathway (the
conversion of glucose to sorbitol) [59]. These effects were not
associated with changes in blood glucose levels or blood
pressure, and they were specific in that the hyperfiltration of
high protein feeding was not modulated by these maneuvers.
The hyperfiltration in diabetic patients has also been favorably
decreased by sorbinil therapy [60].
It is less clear whether increased activity of the polyol
pathway is crucial in the genesis of the altered metabolism of
renal extracellular matrices. Cohen, Klepser and Wu [61] could
not reverse the under-sulfation of GBM proteoglycan by AR!
administration to diabetic rats. Moreover, treatment with Statil,
another ARI, did not reduce the increased levels of laminin B!
mRNA in rat kidneys [40]. However, a significant reduction in
GBM thickness was demonstrated in diabetic rats after several
months of sorbinil therapy [62]. Furthermore, a favorable
response to reduce the microalbuminuria in diabetic rats has
been reported with sorbinil treatment [63].
In our in vitro studies on the effects of elevated ambient
glucose on proximal tubule cell growth and matrix production
we found that the stimulation by high glucose of collagen type
IV secretion and al(IV) mRNA level was abolished when the
cells were treated with 0.1 ma'i sorbinil [641 or when the high
glucose medium was supplemented with 800 tM myo-inositol
[65]. In contrast, the induction of cellular hypertrophy by high
glucose was not modified by AR! treatment or myo-inositol
treatment, suggesting that only particular actions of high glu-
cose media are directly linked to the polyol pathway or to
disturbances in myo-inositol metabolism.
An intriguing pathogenetic link between the products of the
polyol pathway (and other pathways of glucose metabolism)
and the reactions of non-enzymatic glycation has been pro-
posed [66—68]. This is based on the observation that these
glycation reactions can also involve metabolites of glucose
which are the products of the polyol pathway (such as fructose)
[66], and which can be further phosphorylated via novel path-
ways of glucose metabolism that are activated in diabetes
mellitus [67, 68]. Sorbitol-3-phosphate, fructose-3-phosphate
and other unidentified metabolites are increased in erythrocytes
of diabetic subjects and could participate in protein glycation
and cross linking [68].
Several of the manifestations of diabetic nephropathy may
also be a consequence of altered production of local or circu-
lating growth factors and/or modulations in the response to
these factors [6, 9, 16, 69]. Analysis of the role of cytokines in
the pathogenesis of diabetic changes is beyond the scope of this
review. Transforming growth factor-p (TGF-p) deserves special
consideration because it is produced by several cell types
including renal cells, and it has a central role in promoting the
synthesis and the accumulation of different extracellular matrix
moieties [67, 70]. In recent studies [71], we gathered evidence
that elevated ambient glucose levels in proximal tubule cell
cultures increase TBF-f31 mRNA levels and stimulate TBF-13
bioactivity, which in turn may mediate some of the observed
effects of high glucose levels on the cells. The importance of
these observations to the pathogenesis of diabetic nephropathy
will require further analysis.
Summary
TBM thickening and modifications in TBM composition in
diabetes mellitus are primarily the consequence of the meta-
bolic derangements of the disease. In particular, elevated
ambient glucose is a major stimulus for the early induction of
tubule cell hypertrophy and the accompanied increase in tran-
scription and secretion of collagen type IV by these cells. In
vitro studies indicate that increased activity of the polyol
pathway, with the attendant alterations in cellular myo-inositol
metabolism, may mediate the early increase in collagen type IV
biosynthesis by proximal tubule cells. Some of the cellular
effects of high glucose may also be mediated by bioactivation of
local growth factors, such as TGF-f3.
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